Cancer

Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold

Submission of Complete Response to Clinical Hold for HEMO-CAR-T INDLONDON, UK / ACCESSWIRE / January 16, 2024 / Hemogenyx Pharmaceuticals…

5 months ago

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")…

5 months ago

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic…

5 months ago

SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to Be

Cell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotechNEW YORK, Jan.…

5 months ago

Medicenna Announces Appointment of New Auditor

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage…

5 months ago

Defence Begins Trading on the OTCQB and Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or…

5 months ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

5 months ago

Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women

Leader in Women’s Health Encourages Women to Stop Suffering in Silence and Talk to Their Doctor About Disruptive Period SymptomsMARLBOROUGH,…

5 months ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…

5 months ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of…

5 months ago